HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Antigingivitis/Antiplaque Combination With Other Actives Excluded In ANPR

This article was originally published in The Rose Sheet

Executive Summary

FDA's advance notice of proposed rulemaking on OTC antigingivitis/antiplaque products excludes the combination of antigingivitis/antiplaque ingredients with other oral health care ingredients. The 1notice was published in the May 29 Federal Register

Related Content

Mouthwashes and oral cancer
Sinofresh Petition Does Not Support CPC Oral Antiseptic Use – Schering
Oral Care Heavyweights Disagree On Plaque Claim Support, Stannous Fluoride
Antiplaque Claims Spectrum Outlined By WhiteHill
Antiplaque Essential Oil In Vitro Plus In Vivo Test Requirement Urged By Pfizer
CTFA/CHPA Urge Expanded Oral Health Care Indications
Combination Oral Health Care Product Safety Defended By Industry
Sanguinaria oral care safety
CTFA oral health care petition
FDA Should Allow "Qualified" Plaque-Only Cosmetics Claims, WhiteHill Says



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts